Sunitinib 50 MG (Sunitix)

Basic Product Information of Sunitix 50MG (Sunitinib)

How Sunitix 50MG (Sunitinib) Works Multi-Targeted Kinase Inhibition, Anti-Angiogenic and Direct Anti-Tumour Mechanism

Sunitinib, the active ingredient in Sunitix 50MG, is a first-in-class oral multi-targeted receptor tyrosine kinase (RTK) inhibitor that simultaneously inhibits VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, c-Kit (CD117), FLT3 (FMS-like Tyrosine Kinase 3), RET, and CSF-1R (Colony-Stimulating Factor 1 Receptor). This broad but clinically targeted kinase inhibition profile distinguishes Sunitinib from selective single-pathway TKIs and enables dual anti-tumour activity: direct anti-proliferative effects on tumour cells that express oncogenic kinases (particularly c-Kit in GIST and RET in certain tumour subtypes), and anti-angiogenic effects through VEGFR and PDGFR blockade that starve tumours of the blood supply required for growth and metastasis. VEGF-mediated pathological angiogenesis is a dominant driver of tumour progression across multiple solid tumour types, including clear-cell renal cell carcinoma (RCC), gastrointestinal stromal tumours (GIST), and pancreatic neuroendocrine tumours (pNET).

Sunitinib binds to the ATP-binding pocket of VEGFR, PDGFR, c-Kit, FLT3, and RET tyrosine kinases in a competitive manner, preventing ATP from engaging the catalytic site and blocking downstream phosphorylation cascades including the PI3K/AKT, MAPK/ERK, and STAT signalling pathways. In advanced RCC, persistent dysregulation of the VHL–HIF–VEGF axis in clear-cell tumours creates constitutive VEGF overexpression and pathological tumour vascularity; Sunitinib interrupts this axis at the receptor level. In GIST, oncogenic gain-of-function mutations in c-Kit or PDGFR-α drive tumour proliferation; Sunitinib inhibits both wild-type and several imatinib-resistant c-Kit mutant isoforms. Preclinical xenograft studies demonstrated that Sunitinib reduced tumour vascular density by greater than 70% and induced tumour regression in multiple solid tumour models within three weeks of treatment initiation.

Sunitinib has an active primary metabolite, SU12662 (N-desethyl sunitinib), which has a similar potency and kinase inhibition profile to the parent compound and contributes substantially to the total pharmacological activity of each dose. The combined active moiety (sunitinib + SU12662) achieves steady-state plasma concentrations within 10–14 days of the start of each treatment cycle. Oncologists can review the full portfolio of VEGFR inhibitors, targeted therapies, and oncology specialty medicines available from Mediaid Pharmacy for worldwide supply.

Approved Indications for Sunitix 50MG (Sunitinib)

Sunitix (Sunitinib) 50mg is indicated for the following oncological conditions in adult patients:

Key Clinical Benefits of Sunitix (Sunitinib) 50mg

How to Take Sunitix 50MG (Sunitinib) Dosage and Administration Guidelines

Clinical Monitoring Requirements During Sunitix (Sunitinib) Treatment

Regular and systematic clinical monitoring is essential throughout every cycle of Sunitix treatment. Cardiac monitoring is a priority: baseline left ventricular ejection fraction (LVEF) must be assessed by echocardiography or MUGA scan before initiating Sunitinib and repeated periodically during treatment; symptomatic or significant asymptomatic LVEF decline (≥20% from baseline) requires dose interruption or discontinuation. A baseline 12-lead ECG is required for QTc interval measurement; patients with congenital long QT syndrome, congestive heart failure, bradyarrhythmias, or electrolyte abnormalities are at elevated risk and require more frequent ECG monitoring. Blood pressure must be monitored before each treatment cycle and at regular intervals; Sunitinib-induced hypertension occurs in 15–34% of patients and requires antihypertensive therapy; severely uncontrolled hypertension requires temporary dose interruption.

Liver function tests (LFTs) including ALT, AST, total bilirubin, and alkaline phosphatase must be monitored at baseline and before each treatment cycle; if Grade 3–4 hepatotoxicity occurs, withhold Sunitinib pending investigation and permanently discontinue if severe drug-induced liver injury is confirmed. Thyroid function tests (TFTs) TSH, T3, and T4 must be assessed at baseline and at the start of each treatment cycle, as Sunitinib-induced hypothyroidism occurs in approximately 14–40% of patients and typically requires thyroid hormone replacement therapy; hyperthyroidism followed by hypothyroidism has also been reported. Complete blood count (CBC) must be monitored before each treatment cycle, as Grade 3–4 neutropenia and thrombocytopenia are observed in 10–20% of patients depending on the indication; dose modifications are required for severe myelosuppression. Patients must be assessed throughout treatment for signs of haemorrhagic events, thrombotic microangiopathy, gastrointestinal perforation or fistula, osteonecrosis of the jaw, adrenal insufficiency, and tumour lysis syndrome. Blood glucose should be monitored periodically, particularly in diabetic patients, as Sunitinib can cause significant hypoglycaemia in this population.

Drug Interactions and Important Safety Information for Sunitix (Sunitinib)

Sunitinib is metabolised primarily by hepatic CYP3A4 enzymes to its active metabolite SU12662. Strong CYP3A4 inhibitors including ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit juice substantially increase the combined Sunitinib and SU12662 plasma exposure; ketoconazole co-administration increased Sunitinib AUC by approximately 49%. Strong CYP3A4 inducers including rifampicin, carbamazepine, phenytoin, phenobarbital, dexamethasone, and St. John’s Wort significantly reduce Sunitinib and SU12662 plasma concentrations and clinical efficacy; rifampicin reduced Sunitinib AUC by approximately 46%.

Concomitant use of agents known to prolong the QTc interval including Class IA and III antiarrhythmics, certain antipsychotics, tricyclic antidepressants, methadone, and fluoroquinolone antibiotics must be avoided due to additive QTc prolongation risk from Sunitinib. Patients receiving anticoagulants particularly warfarin require more frequent INR and prothrombin time monitoring throughout Sunitinib treatment, as the interaction is unpredictable and both supratherapeutic and subtherapeutic anticoagulation have been reported; low molecular weight heparin (LMWH) is preferred where anticoagulation is required. The combination of Sunitinib with bevacizumab was associated with increased mortality and dose-limiting toxicity in a Phase I RCC trial and must not be used. Patients must declare all current medications, supplements, and herbal products to their oncologist before starting Sunitix.

Side Effects and Precautions of Sunitix (Sunitinib)

Who Should Use Sunitix 50MG (Sunitinib)?

Sunitix (Sunitinib) 50mg is indicated for three distinct adult patient populations. In advanced Renal Cell Carcinoma (RCC), Sunitix is the first-line standard of care for patients with metastatic or unresectable clear-cell RCC who have not previously received systemic therapy for advanced disease; histopathological confirmation of clear-cell histology is required, as evidence in non-clear-cell RCC subtypes is limited. In Gastrointestinal Stromal Tumour (GIST), Sunitix is indicated for patients who have experienced disease progression on imatinib mesylate or who are intolerant of imatinib; prior documentation of imatinib treatment and progression is required, and oncologists should confirm c-Kit or PDGFR-α mutation status where possible to guide treatment decisions. In progressive Pancreatic Neuroendocrine Tumours (pNET), Sunitix is indicated for patients with well-differentiated, progressive, locally advanced or metastatic pNET; histopathological confirmation of well-differentiated (Grade 1 or 2) tumour morphology and NET origin in the pancreas is required before initiating therapy. Sunitix must be prescribed and supervised by a qualified oncologist with experience in targeted anticancer therapies and molecular oncology. A comprehensive pre-treatment assessment including cardiac evaluation (LVEF, ECG), LFTs, TFTs, CBC, blood pressure, and renal function is mandatory before initiating each patient on Sunitix. Healthcare providers seeking a comprehensive source for oncology specialty medicines including VEGFR inhibitors, targeted therapies for RCC, GIST, pNET, and other solid tumours can consult Mediaid Pharmacy’s oncology portfolio for global availability and worldwide supply.

Manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh

Beacon Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh and the number one oncology and specialty medicine company in the country. Beacon was the first company in Bangladesh to export cancer medicines and currently exports to markets across Asia, Africa, Europe, and Latin America. With more than 200 generic drugs and 65 oncology products in its portfolio, Beacon operates under strict WHO-GMP, cGMP, and ISO-certified manufacturing standards. Sunitix (Sunitinib) 50mg is one of Beacon’s core targeted oncology products, offering a high-quality, bioequivalent, and cost-accessible alternative to Sutent (Pfizer) enabling oncologists and patients in Bangladesh, Sri Lanka, Nepal, and globally to access proven multi-kinase-targeted therapy across RCC, GIST, and pNET without the financial barriers of originator pricing.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Sunitix (Sunitinib)

Mediaid Pharmacy is a trusted global supplier of specialty oncology and targeted therapy medications. Sunitix (Sunitinib) 50mg is available through Mediaid Pharmacy with reliable worldwide shipping to South Asia, the Middle East, Africa, Europe, and beyond. Our team provides full order support including pricing, availability confirmation, documentation, and delivery tracking for oncologists, hospitals, and patients requiring Sunitix internationally. Contact Mediaid Pharmacy directly via WhatsApp, phone, or WeChat for enquiries about availability and delivery to your country.

Why Choose Sunitix (Sunitinib) from Mediaid Pharmacy?

Sunitix represents a clinically validated and cost-accessible option for the multi-targeted treatment of advanced RCC, imatinib-resistant GIST, and progressive pNET. As the generic bioequivalent of Sutent (Pfizer), Sunitix delivers the same active ingredient Sunitinib with the same proven VEGFR, PDGFR, c-Kit, FLT3, and RET inhibition mechanism, at a dramatically lower price that enables patients to sustain therapy across the multiple cycles required for optimal oncological benefit. The 50mg capsule formulation in a convenient 6-capsule pack allows flexible ordering aligned to the Schedule 4/2 treatment cycle structure, with Mediaid Pharmacy able to supply the quantities required for complete treatment cycles. Manufactured by Beacon Pharmaceuticals Ltd. under WHO-GMP and cGMP standards, and registered in Bangladesh, Sri Lanka, and Nepal, Sunitix is distributed globally by Mediaid Pharmacy as the trusted choice for oncologists and patients seeking proven multi-kinase-targeted therapy without financial barriers. For the complete range of oncology medicines available from Mediaid Pharmacy, including VEGFR inhibitors, GIST-targeted therapies, and other solid tumour treatments, visit our oncology medicines page.

Frequently Asked Questions About Sunitix 50MG (Sunitinib)